Equity Overview
Price & Market Data
Price: $1.20
Daily Change: $0.00 / 0.00%
Daily Range: $0.502 - $1.95
Market Cap: $22,136,526
Daily Volume: 417,565,050
Performance Metrics
1 Week: 121.4%
1 Month: 96.82%
3 Months: 35.93%
6 Months: -17.24%
1 Year: -26.83%
YTD: 35.93%
Company Details
Employees: 9
Sector: Technology services
Industry: Packaged software
Country: United States
Details
Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.